Distinct phenotypes in the preeclamptic-like mouse model induced by adenovirus carrying sFlt1 and recombinant sFlt1 protein by Yingying Wei, Haojun Tian, Xuancheng Wei, Ai Zhang, Mengtian Wei, Ruixue Wang, Lu Zhang, Ping Qiao, Kai Wang

Subjects: Get full text

Pharmacokinetics of 7,8-dihydroxyflavone in neonatal mice with hypoxia-ischemia related brain injury by Sin Yin Lim, Cameron O. Scarlett, Sefer Yapici, Peter Ferrazzano, Peter Ferrazzano, Pelin Cengiz, Pelin Cengiz

Subjects: Get full text

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality by Jain Nem Kumar, Tailang Mukul, Thangavel Neelaveni, Makeen Hafiz A., Albratty Mohammed, Najmi Asim, Alhazmi Hassan Ahmad, Zoghebi Khalid, Alagusundaram Muthumanickam, Jain Hemant Kumar, Chandrasekaran Balakumar

Subjects: Get full text

Vitiligo-like lesions following imatinib mesylate therapy: a case series and review of literature by Neerja Saraswat, Shekhar Neema, Sushil Kumar

Subjects: Get full text

Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma by Dan Liu, Xia Yin, Hui Wang, Lijie Xing, Ping Li, Haichen Wei, Ji Ma, Qiang He, Linna Xie, Ke Lu, Zengjun Li

Subjects: Get full text

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients by Yan-Jei Tang, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu

Subjects: Get full text

Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations by Masato Kikuta, Sei Naito, Takahiro Osawa, Kazuyuki Numakura, Takafumi Narisawa, Yuki Takai, Mayu Yagi, Yuya Sekine, Ojiro Tokairin, Nobuo Shinohara, Tomonori Habuchi, Norihiko Tsuchiya

Subjects: “…Renal cell carcinoma; Tyrosine kinase inhibitor…”
Get full text

A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022 by TAN Meijuan, YANG Shijie, XU Xiequn

Subjects: Get full text

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors? by Cristina Maria Failla, Maria Luigia Carbone, Carmela Ramondino, Emanuele Bruni, Angela Orecchia

Subjects: Get full text

Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia by Abhishek Abhishek, Jonathan A Cook, Helen M Parry, Anne Francis, Lelia Duley, Vicki S Barber, Paul Moss, Nicholas Peckham

“…This study aims to determine in patients with chronic lymphocytic leukaemia (CLL) if a 3-week pause in Bruton tyrosine kinase inhibitor therapy (BTKi) starting 1 week before delivery of SARS-CoV-2 vaccine booster, improves vaccine immune response when compared with continuation of BTKi.Methods and analysis An open-label, randomised controlled superiority trial will be conducted in haematology clinics in approximately 10 UK National Health Service (NHS) hospitals. …”
Get full text

Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case by Huiyun Lv, Wei Liu, Yang Zhang, Chen Song

Subjects: Get full text

Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age by Mototsugu Oya, Taito Ito, Masashi Sato, Makiko Morita, Masahiro Kajita, Norio Nonomura

Subjects: Get full text

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II by Hu Jiaming, Zhang Minghui, Liu Huiqiang, Zhang Zongli, Xu Yunfei

Subjects: Get full text

STAT1/STAT3 Gain of Function and Mechanisms of Immune Dysregulation by Ayça Kıykım

Subjects: “…janus tyrosine kinase…”
Get full text

Assessment of efficacy and safety of imatinib as an adjunct host-targeted therapy for parasite clearance in chloroquine-resistant malaria: a prospective case control study by Fazeel Zubair Ahmed, Shaifulla P

Subjects: Get full text

Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges by Sofija Kozarac, Jelena Ivanovic, Marko Mitrovic, Kristina Tomic Vujovic, Isidora Arsenovic, Nada Suvajdzic-Vukovic, Nada Suvajdzic-Vukovic, Andrija Bogdanovic, Andrija Bogdanovic, Ana Vidovic, Ana Vidovic, Milena Todorovic-Balint, Milena Todorovic-Balint, Jelena Bila, Jelena Bila, Mirjana Mitrovic, Mirjana Mitrovic, Danijela Lekovic, Danijela Lekovic, Irena Djunic, Irena Djunic, Marijana Virijevic, Marijana Virijevic, Aleksandar Trivic, Aleksandar Trivic, Jelena Micic, Jelena Micic, Darko Antic, Darko Antic

Subjects: Get full text

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada by Lara Chayab, Natasha B. Leighl, Mina Tadrous, Christine M. Warren, William W. L. Wong

Get full text

The improved prognosis of <i>FLT3</i>-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data by Matthew Schwede, Gladys Rodriguez, Vanessa E. Kennedy, Solomon Henry, Douglas Wood, Gabriel N. Mannis, Ravindra Majeti, Jonathan H. Chen, Eran Bendavid, Tian Yi Zhang

Get full text

RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015 by A. M. Popov, O. B. Karyakin, A. D. Kaprin

Subjects: Get full text

Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India by Sangita A. Vanik, Dhaval Jetly, Biren Parikh, Karthik Dhandapani, Rukmini Bezbaruah

Subjects: Get full text